Assignee
GENZYME CORP
US·693 granted patents·392 pending applications·21,700 citations·filing 1984–2025
Top patents by PatentIndex Score
1,085 records- 0198US11911440B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted Feb 27, 2024·5 cites·20 claims
- 0298US7846729B2Metabolically activated recombinant viral vectors and methods for their preparation and useGENZYME CORP·Filed 2007·Granted Dec 7, 2010·75 cites·9 claims
- 0398US7811757B2Methods for disease detectionGENZYME CORP·Filed 2006·Granted Oct 12, 2010·100 cites·12 claims
- 0498US7785888B2Metabolically activated recombinant viral vectors and methods for their preparation and useGENZYME CORP·Filed 2006·Granted Aug 31, 2010·74 cites·6 claims
- 0598US7704492B2Methods for delivering DNA to muscle cells using recombinant adeno-associated virus virionsGENZYME CORP·Filed 2008·Granted Apr 27, 2010·45 cites·17 claims
- 0698US7341720B2Targeting of glycoprotein therapeuticsGENZYME CORP·Filed 2006·Granted Mar 11, 2008·85 cites·18 claims
- 0798US6521223B1Single phase gels for the prevention of adhesionsGENZYME CORP·Filed 2000·Granted Feb 18, 2003·206 cites·15 claims
- 0898US6162208AArticulating endoscopic implant rotator surgical apparatus and method for using sameGENZYME CORP·Filed 1998·Granted Dec 19, 2000·2.2k cites·33 claims
- 0997US11975043B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2022·Granted May 7, 2024·3 cites·33 claims
- 1097US9790268B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2014·Granted Oct 17, 2017·29 cites·39 claims
- 1197US8383780B2Antibodies to TGFβGENZYME CORP·Filed 2010·Granted Feb 26, 2013·66 cites·6 claims
- 1297US7704721B2Compositions and methods to prevent AAV vector aggregationGENZYME CORP·Filed 2005·Granted Apr 27, 2010·74 cites·11 claims
- 1397US7427396B2AAV vectors for gene delivery to the lungGENZYME CORP·Filed 2005·Granted Sep 23, 2008·149 cites·4 claims
- 1497US6923986B2Multiblock biodegradable hydrogels for drug delivery and tissue treatmentGENZYME CORP·Filed 2003·Granted Aug 2, 2005·63 cites·13 claims
- 1597US6858203B2Method of making phosphate-binding polymers for oral administrationGENZYME CORP·Filed 2002·Granted Feb 22, 2005·85 cites·18 claims
- 1697US6855830B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2002·Granted Feb 15, 2005·67 cites·2 claims
- 1797US6733780B1Direct compression polymer tablet coreGENZYME CORP·Filed 2000·Granted May 11, 2004·122 cites·19 claims
- 1897US6099832ATransplants for myocardial scarsGENZYME CORP·Filed 1998·Granted Aug 8, 2000·259 cites·23 claims
- 1997US5882877AAdenoviral vectors for gene therapy containing deletions in the adenoviral genomeGENZYME CORP·Filed 1997·Granted Mar 16, 1999·338 cites·21 claims
- 2097US5670488AAdenovirus vector for gene therapyGENZYME CORP·Filed 1993·Granted Sep 23, 1997·358 cites·19 claims
- 2196US12434008B1Lock ring for a medicament delivery deviceGENZYME CORP·Filed 2025·Granted Oct 7, 2025·2 cites·21 claims
- 2296US11878024B2Tropomyosin-related kinase (Trk) inhibitorsGENZYME CORP·Filed 2022·Granted Jan 23, 2024·3 cites·6 claims
- 2396US11406644B2Tropomyosin-related kinase (TRK) inhibitorsGENZYME CORP·Filed 2020·Granted Aug 9, 2022·5 cites·21 claims
- 2496US11130816B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2019·Granted Sep 28, 2021·6 cites·20 claims
- 2596US10836813B2Fc containing polypeptides with altered glycosylation and reduced effector functionGENZYME CORP·Filed 2017·Granted Nov 17, 2020·11 cites·23 claims
- 2696US10369193B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2016·Granted Aug 6, 2019·17 cites·13 claims
- 2796US9657056B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2015·Granted May 23, 2017·22 cites·29 claims
- 2896US8007780B2AAV vectors for gene delivery to the lungGENZYME CORP·Filed 2008·Granted Aug 30, 2011·69 cites·7 claims
- 2996US7863293B2CXCR4 chemokine receptor binding compoundsGENZYME CORP·Filed 2007·Granted Jan 4, 2011·24 cites·18 claims
- 3096US7763738B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2007·Granted Jul 27, 2010·28 cites·5 claims
- 3196US7455248B2Powder delivery deviceGENZYME CORP·Filed 2005·Granted Nov 25, 2008·63 cites·23 claims
- 3296US7371366B2GlcNAc phosphotransferase of the lysosomal targeting pathwayGENZYME CORP·Filed 2005·Granted May 13, 2008·31 cites·2 claims
- 3396US7196205B2Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitorsGENZYME CORP·Filed 2005·Granted Mar 27, 2007·51 cites·16 claims
- 3496US7087583B2Sequence specific DNA binding by p53GENZYME CORP·Filed 2001·Granted Aug 8, 2006·64 cites·16 claims
- 3596US7008635B1Hydrogels for orthopedic repairGENZYME CORP·Filed 2000·Granted Mar 7, 2006·93 cites·15 claims
- 3696US7001994B2Methods for introducing mannose 6-phosphate and other oligosaccharides onto glycoproteinsGENZYME CORP·Filed 2002·Granted Feb 21, 2006·84 cites·19 claims
- 3796US6682730B2Transplants for myocardial scarsGENZYME CORP·Filed 2002·Granted Jan 27, 2004·68 cites·12 claims
- 3896US6432927B1Compositions and methods for inducing gene expressionGENZYME CORP·Filed 2000·Granted Aug 13, 2002·62 cites·31 claims
- 3996US6419928B1Monoclonal antibodies to transforming growth factor-beta and methods of useGENZYME CORP·Filed 2000·Granted Jul 16, 2002·84 cites·9 claims
- 4096US5948767ACationic amphiphile/DNA complexesGENZYME CORP·Filed 1996·Granted Sep 7, 1999·271 cites·13 claims
- 4196US5824544AAdenovirus vectors for gene therapyGENZYME CORP·Filed 1995·Granted Oct 20, 1998·261 cites·6 claims
- 4295US12110338B2Site-specific antibody-drug conjugation through glycoengineeringGENZYME CORP·Filed 2021·Granted Oct 8, 2024·2 cites·29 claims
- 4395US11807690B2Hyperglycosylated binding polypeptidesGENZYME CORP·Filed 2019·Granted Nov 7, 2023·4 cites·17 claims
- 4495US10995148B2Site-specific glycoengineering of targeting moietiesGENZYME CORP·Filed 2015·Granted May 4, 2021·8 cites·39 claims
- 4595US10954230B2Method of preparing glucosylceramide synthase inhibitorsGENZYME CORP·Filed 2020·Granted Mar 23, 2021·4 cites·3 claims
- 4695US9650413B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2015·Granted May 16, 2017·22 cites·37 claims
- 4795US9650412B2Integrated continuous manufacturing of therapeutic protein drug substancesGENZYME CORP·Filed 2014·Granted May 16, 2017·34 cites·26 claims
- 4895US9492415B2Methods of treating Parkinson's disease using viral vectorsGENZYME CORP·Filed 2012·Granted Nov 15, 2016·16 cites·8 claims
- 4995US9415119B2Gene therapy for neurodegenerative disordersGENZYME CORP·Filed 2015·Granted Aug 16, 2016·13 cites·7 claims
- 5095US7935692B2Methods to mobilize progenitor/stem cellsGENZYME CORP·Filed 2005·Granted May 3, 2011·29 cites·26 claims
Showing the top 50 of 1,085 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when GENZYME CORP files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →